Specify a stock or a cryptocurrency in the search bar to get a summary
Shanghai HeartCare Med Tech
6609Shanghai HeartCare Medical Technology Corporation Limited researches, develops, manufacture, and sells neuro-interventional medical devices in Mainland China. The company offers ischemic stroke thrombectomy devices, such as Captor thrombectomy device, and aspiration catheter and pump; intracranial stenosis treatment devices comprising intracranial drug-eluting balloon catheter and embolization protection system; hemorrhagic stroke treatment devices, including coil embolization assistant stent and flow diverter device; and ischemic stroke prevention devices, such as LAA occlude. It also provides vascular access devices comprising distal access catheter, microcatheter, balloon guiding catheter, vascular closure device, support catheter, neuro-interventional microcatheter, micro guidewire, microcatheter for coiling, microcatheter for flow diverter device, and navigation catheter. The company's products are used for acute ischemic stroke and neurovascular stenosis treatment, hemorrhagic stroke treatment, ischemic stroke prevention, and interventional access. Shanghai HeartCare Medical Technology Corporation Limited was incorporated in 2016 and is headquartered in Shanghai, the People's Republic of China. Address: Building 38, Shanghai, China
Analytics
WallStreet Target Price
155.58 HKDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 6609
Dividend Analytics 6609
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 6609
Stock Valuation 6609
Financials 6609
Results | 2019 | Dynamics |